Of these, 135 women underwent germline LS testing for the following indications: MSI-H MMR deficient tumour with normal MLH1-methylation (n = 6); MSI-H MMR deficient tumour (MLH1-methylation testing not indicated; n = 13); MMR deficient and MSS/MSI-L (n = 19); MSI-H MMR-proficient tumour (n = 6); age ≤50 years (n = 35); and strong family history (n = 12). Here, MLH1 is linked to neoplasm.